Mallinckrodt posts Q4 loss on acquisitions; confirms it’s suing FDA

Mallinckrodt PLC reported fiscal fourth-quarter net sales of $789.3 million, up 44.8 percent from the prior-year quarter, driven up by the inclusion of injection drugs acquired earlier this year and the continued strength of its portfolio of specialty controlled substance generics...